M&A Deal Summary |
|
|---|---|
| Date | 2023-04-24 |
| Target | Radian |
| Sector | Medical Products |
| Buyer(s) | Axonics |
| Sellers(s) | Intermed Labs |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Medical Products |
| Revenue | 274M USD (2022) |
Axonics is focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The Axonics product portfolio includes the Axonics R20TM and the Axonics F15TM Systems used to deliver sacral neuromodulation (SNM) therapy. SNM therapy is a minimally invasive procedure used in the treatment of OAB and fecal incontinence. It works by delivering mild electrical pulses to the sacral nerve to restore communication between the brain and the bladder. Axonics was founded in 2013 and is headquartered in Irvine, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products M&A | 2 of 2 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-25 |
Contura
London, United Kingdom Contura Ltd. specializes in the distribution and sale of healthcare products, both pharmaceuticals, and medical devices, focused primarily on women’s health. Its lead products are Bulkamid, Aquamid, Regurin XL, and Cystistat. It also has a number of ongoing development programs focused upon additional uses of its proprietary hydrogel technology, such as Arthrosamid for the treatment of osteoarthritis in the knee. Contura is based in London, United Kingdom. |
Buy | $200M |
Intermed Labs is an innovation lab and startup studio that advances technological breakthroughs in Health Technology. Intermed Labs is based in United States.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
